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A B S T R A C T
Background: Motor complications represent an important clinical problem in the treatment of Parkinson's dis-
ease (PD). The Motor Complications Part of the Movement Disorder Society-sponsored Uniﬁed Parkinson's
Disease Rating Scale (MDS-UPDRS Part IV) and the Uniﬁed Dyskinesia Rating Scale (UDysRS) are among the
most reliable instruments to evaluate these problems. The minimal clinically important diﬀerence thresholds are
the smallest changes in the outcome measures that are clinically meaningful.
Aims: The aim of our study was to calculate the minimal clinically important diﬀerence thresholds for the MDS-
UPDRS Part IV and the historic parts of the UDysRS.
Methods: A total of 1044 paired investigations of 436 patients were analyzed. Changes in the respective outcome
measures (MDS-UPDRS Part IV, UDysRS Parts I and II) were compared to the Patient-rated Global Impression of
Improvement scores (anchors). Subsequently, we applied receiver-operating characteristic analysis to ascertain
the MCID thresholds with optimal sensitivity and speciﬁcity.
Results: Any improvement greater than 2.1 points or any worsening greater than 1.8 points on UDysRS Part I
represents a minimal, yet clinically meaningful change. In reference to UDysRS Part II, the smallest changes
considered clinically relevant are 1.8 and 1.7 points for improvement and deterioration, respectively. The
thresholds for the MDS-UPDRS Part IV are 0.9 points for improvement and 0.8 points for worsening.
Conclusions: Our estimates may allow the judgment of the clinical relevance of numeric changes in the dyski-
nesia scales.
1. Introduction
Parkinson's disease (PD) is the second most frequent neurodegen-
erative disorder. Current therapeutic approaches have mainly sys-
tematic eﬀects on the motor and non-motor symptoms of the disorder.
As the disease progresses, the therapeutic eﬃcacy of antiparkinsonian
medication becomes more and more limited, and motor complications
inevitably develop. Wearing oﬀ, on-oﬀ ﬂuctuations, peak of dose dys-
kinesia, biphasic dyskinesia, and mainly OFF state dystonia are the
most common long-term problems of the dopaminergic drugs. Many
therapeutic approaches, including oral combinations, deep brain
stimulation (DBS), levodopa/carbidopa intestinal gel infusion (LCIG),
and apomorphine pump treatments, aim to improve the symptoms of
PD and reduce the motor and non-motor complications simultaneously.
A growing number of interventional trials aimed at reducing the motor
complications have been published recently. To judge their eﬃcacy,
valid and reliable clinical outcome measures are warranted.
Recently a single, comprehensive rating scale, called the Uniﬁed
Dyskinesia Rating Scale (UDysRS), was developed to assess the most
important dimensions of motor complications [1]. The development of
the scale was mainly clinimetrically driven [2] to simultaneously and
reliably measure various aspects of the motor complications [3]. The
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UDysRS consists of four diﬀerent subscales representing diﬀerent do-
mains:
• Part 1 ON Dyskinesia measures the subjective impact of ON dys-
kinesia on everyday activities. The ﬁrst item on the time spent with
ON dyskinesia is assessed by a trained rater (Part 1 A), whereas the
remaining 10 items (Part 1 B) are self-rated by patients.
• Part 2 OFF Dystonia evaluates the burden caused by OFF dystonia.
The ﬁrst item on the time spent with OFF dystonia is evaluated by a
trained rater (Part 2 A), and the remaining three items (Part 2 B) are
completed by patients.
• Part 3 Impairment assesses the tropical distribution and severity of
dyskinesia.
• Part 4 Disability examines the disability associated with dyskinesia
on four representative tasks, including communication, drinking,
dressing, and ambulation.
With the exception of the ﬁrst questions assessing the time spent
with ON dyskinesia and OFF dystonia, Parts 1 and 2 form a self-rated
questionnaire, a type of patient-reported outcome (PRO) commonly
referred as the “historic” sections of the UDysRS. Parts 3 and 4 are
assessed by clinicians (clinician-rated outcome, CRO) usually denoted
as “objective” parts of the UDysRS [1]. While the individual subscales
can be evaluated independently, the total score of the UDysRS can also
be calculated by summing the scores on the four domains [1]. Recent
studies have demonstrated that the UDysRS simultaneously has a good
temporal stability [4] and a reliable responsiveness measuring changes
in motor complications [5]. Moreover, the UDysRS can also be used
reliably over the Web [6], making it a feasible instrument for patients
unable to physically attend their physician's oﬃce. Another advantage
of the scale is the development of numerous oﬃcial language versions
[7–9] in accordance with the strict rules for validation [2].
In addition to UDysRS, the Motor Complications part of the
Movement Disorder Society-sponsored Uniﬁed Parkinson's Disease
Rating Scale (MDS-UPDRS MC, Part IV) [10] is also capable of mea-
suring the motor complications in a simple, less detailed and compre-
hensive, yet commonly reported, way.
In biomedical research, statistical signiﬁcance does not necessarily
imply clinical relevance. Because small changes in the outcome mea-
sures do not unequivocally have clinical meaning, the concept of the
minimal clinically important diﬀerence (MCID) has been introduced.
The MCID represents the smallest changes in an outcome that the pa-
tient acknowledges as meaningful. At this time, only limited data are
available on the MCID thresholds of the dyskinesia rating scales.
Although Mestre et al. [11] demonstrated that a 2.32-point change on
the clinician-rated UDysRS Part 3 is the threshold for clinical relevance,
the MCID estimates for the historic parts of the UDysRS have not yet
been calculated. Although our team evaluated the MCID thresholds for
Parts I [12], II [12], III [13], and the total score [14] of the MDS-
UPDRS, the size of the minimally required change on the MDS-UPDRS
MC is still unknown.
Fulﬁlling this clinical need, we aimed to evaluate the MCID
thresholds for the recently published dyskinesia scales, the MDS-UPDRS
MC and the historic parts of the UDysRS.
2. Materials and methods
The study protocol was similar to the procedure of measuring the
MCID thresholds for the motor and non-motor experiences of daily
living parts of the MDS-UPDRS [12]. A total of 436 patients with PD
and motor complications at baseline were enrolled and sequentially
examined every 6 months. The study was approved by the Regional and
Institutional Ethical Committee (3617.316–24987/KK41). Besides de-
mographic-, medication-, and disease-related data, the validated Hun-
garian versions of the MDS-UPDRS [15] and UDysRS [8] were assessed.
At follow-up visits, both the Clinician-reported Global Impression of
Improvement (CGI-I) and the Patient-rated Global Impression of Im-
provement (PGI-I) [16] scales were obtained to measure the perceived
changes in the motor complications since the last examination. Subjects
with the major neurocognitive disorder were excluded (Montreal Cog-
nitive Assessment score < 20.5) [17], [18]. The severity of PD was
categorized based on the Hoehn-Yahr Stage (HYS) as mild (HYS 1 and
2), moderate (HYS 3), and severe (HYS 4 and 5) [19].
Following the recommendations of Revicki et al. [20], both anchor-
and distribution-based methods were used for the MCID calculations
[20]. Clinimetrically, the anchor for MCID calculations should be an
independent and clinically relevant instrument that is simultaneously
interpretable by itself and correlates with the outcome measure being
evaluated [20,21]. First, we tested whether the CGI-I or PGI-I is feasible
by calculating the Spearman correlation coeﬃcients between the
changes in dyskinesia scores and the potential anchors. As a minimum
of 0.3 is required for the correlation coeﬃcient [20], the PGI-I was
chosen for further analyses (Supplementary data). We performed or-
dinal regression modeling between the PGI-I (dependent value) and the
changes in the evaluated dyskinesia scores to verify its feasibility as an
anchor [12]. The detailed methods for MCID threshold calculations
were published previously [13]. First, we compared the changes in
dyskinesia measures with the PGI-I score 4 (no change) with the
changes in the dyskinesia scales associated with PGI-I score 3 (minimal
improvement) and PGI-I score 5 (minimal worsening). Subsequently,
we applied the receiver-operating characteristic (ROC) technique to
identify the optimal threshold values with the highest sensitivity and
speciﬁcity. Finally, eﬀect size calculations (Cohen d) were performed
[22]. In optimal cases, both anchor-based calculations should yield si-
milar MCID values [20,23], representing an approximately 0.2 eﬀect
size [20,22].
3. Results
The 1044 paired visits of 436 patients with PD were analyzed. The
median number of return visits was 2. The baseline characteristics of
the patients and the changes in the antiparkinsonian treatment are
displayed as Supplementary data. We could build statistically sig-
niﬁcant ordinal regression models between the PGI-I and the changes in
the dyskinesia scales (Nagelkerke pseudo-R-square values: 0.378,
0.397, and 0.328 for UDysRS Part 1, UDysRS Part 2, and MDS-UPDRS
MC, respectively; p < 0.05 in all instances).
The mean change in the dyskinesia scores in the group of patients
having a PGI-I score of 4 was negligible, with the eﬀect size varying
between 0.01 and 0.04. Table 1 shows the mean changes, the eﬀect size,
and the speciﬁcity and sensitivity values denoting the full dataset; the
MCID estimates for the diﬀerent severity stages are shown in Table 2.
4. Discussion
Although an increasing number studies use the UDysRS Parts 1 and
2 and the MDS-UPDRS MC as their outcome measures, the MCID
thresholds for these instruments had not yet been evaluated. Therefore,
the results of these studies could only be judged from the statistical
point of view. Following the recommendations of Revicki et al. [20], we
aimed to calculate these MCID thresholds, providing a judgment for
further clinical practice. We demonstrated that any improvement
greater than 2.1 points or any worsening greater than 1.8 points on
UDysRS Part 1 represents a minimal, yet clinically meaningful change.
In reference to UDysRS Part 2, the smallest changes considered clini-
cally relevant are 1.8 and 1.7 points for improvement and deterioration,
respectively. The thresholds for the MDS-UPDRS MC are 0.9 points for
improvement and 0.8 points for worsening.
The strength of our approach was the simultaneous use of various
anchor- and distribution-based methods giving similar MCID estima-
tions. The relatively large number of enrolled patients and a wide range
of disease severity examined can further ensure the reliability and
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applicability of our calculations.
To the best of our knowledge, our study is the ﬁrst establishing the
MCID thresholds for the UDysRS Parts 1 and 2 and MDS-UPDRS MC.
Therefore, we cannot compare our results to those of other groups.
In a PubMed search performed on February 15, 2018 (key words:
“Uniﬁed Dyskinesia Rating Scale” and “Parkinson's disease”), we
identiﬁed 6 studies reporting changes in UDysRS subscales as their
outcomes.
In a randomized and controlled pilot trial, Fox et al. examined the
eﬀectiveness of the sigma-1 receptor-agonist and glutamatergic/
monoaminergic modulator, dextromethorphan, plus quinidine for
treating levodopa-induced dyskinesia [24]. Their secondary endpoints
included several dyskinesia/motor assessments. Although statistical
signiﬁcance was not reached (p values 0.057–0.407), the observed
changes in MDS-UPDRS MC and UDysRS Part 1 were clinically im-
portant (−2.7 and −4.0, respectively) [24]. On the other hand,
changes in UDysRS Part 2 were neither statistically, nor clinically, re-
levant.
Three diﬀerent articles have been published on the eﬃcacy of ADS-
5102 (Amantadine extended release) in PD with motor complications
[25–27]. None of these studies reported the changes in the individual
UDysRS subscales; only the composite scores (i.e., total score) were
published. Except for the dose of 260mg, the MDS-UPDRS MC scores
improved in both statistically signiﬁcant and clinically relevant man-
ners. In their pooled analysis published recently [28], changes in the
MDS-UPDRS MC showed a clinically important treatment eﬀect for
ADS-5102 at week 12 [mean change: −2.3, 95th conﬁdence interval
(CI): −3.2 and −1.5, p < 0.0001].
Juhasz et al. evaluated the eﬀects of LCIG on the motor complica-
tion in a prospective, multicenter and an open-label trial. A total of 34
subjects ﬁnished the study. All dyskinesia-related outcomes demon-
strated statistically signiﬁcant improvement (UDysRS Part 1 from
20.5 ± 8.6 to 14.5 ± 9.3 points, UDysRS Part 2 from 9.5 ± 4.7 to
6.3 ± 4.2 points, and MDS-UPDRS MC from 10.4 ± 4.0 to 7.5 ± 4.0
points, p < 0.01 in all cases), which also meet our criteria for clinical
relevance [29].
In another prospective trial, Juhasz et al. examined the eﬃcacy of
bilateral subthalamic DBS therapy on dyskinesia. Of note, the changes
in the UDysRS total score was the primary outcome. Based on the data
of 71 consecutive patients, the authors showed an 11.7 ± 8.4 point
and 5.7 ± 5.0 point decrease on UDysRS Parts 1 and 2, whereas the
MDS-UPDRS MC scores were lowered by 4.0 ± 3.6 points. Again, these
results can be considered as both statistically and clinically relevant
[30].
In conclusion, the UDysRS and MDS-UPDRS MC tests have been
successfully applied in numerous interventional studies measuring the
changes in dyskinesia. Our MCID estimations can provide guidance on
judging the relevance of the results of the published and future trials
from a clinical perspective.
Table 1
Mean changes in certain UDysRS and MDS-UPDRS scores compared to Patient-rated Global Impression of Improvement scores.
Instrument PGI-I Number of
paired visits







Sensitivity Speciﬁcity LR+ LR-




248 −2.1 3.9 −3.7 −1.5 0.20 −2.5 0.562 0.644 1.601 0.699
4 the same 386 −0.5 3.7 −1.3 0.9 0.02 NA
5 a little
worse
203 1.8 3.8 0.9 3.2 0.18 1.5 0.577 0.597 1297 0.802




248 −1.8 2.7 −2.9 1.5 0.21 −1.5 0.654 0.701 1.718 0.621
4 the same 386 0.0 2.9 −0.5 0.6 0.01 NA
5 a little
worse
203 1.7 3.2 0.7 2.4 0.19 1.5 0.676 0.623 1.207 0.830
MDS-UPDRS Part IV 3 a little
better
248 −0.9 3.5 −1.4 −0.4 0.18 −0.5 0.524 0.634 1.402 0.724
4 the same 386 −0,2 3.1 −0.9 0.3 0.01 NA
5 a little
worse
203 0.8 3.6 0.4 1.3 0.15 0.5 0.582 0.597 1251 0801
The number of return visits did not appreciably alter these values.
Abbreviations: CI = Conﬁdence interval; +LR: Positive likelihood ratio; -LR: Negative likelihood ratio; MDS-UPDRS = Movement Disorders Society Sponsored
version of Uniﬁed Parkinson's Disease Rating Scale; PGI-I = Patient-rated Global Impression of Improvement; ROC=receiver operating characteristic analysis;
UDysRS=Uniﬁed Dyskinesia Rating Scale.
Table 2
Minimal clinically important diﬀerence threshold values based on disease severity.
Instrument PGI-I Disease severity (Hoehn-Yahr Stage)
Mild (HYS 1&2) Moderate (HYS 3) Severe (HYS 4&5) Overall (HYS 1–5)
UDysRS Part I (On Dyskinesia) 3 a little better −2.4 −2.0 −2.5 −2.1
4 the same −0.4 −0.7 −0.5 −0.5
5 a little worse 1.4 2.2 2.4 1.8
UDysRS Part II (OFF Dystonia) 3 a little better −1.4 −1.9 −2.2 −1.8
4 the same −0.1 0.1 0.2 0.0
5 a little worse 1.3 1.8 2.0 1.7
MDS-UPDRS Part IV 3 a little better −0.8 −1.1 −1.3 −0.9
4 the same 0.1 −0.1 −0.3 −0,2
5 a little worse 1.1 0.7 1.0 0.8
Abbreviations: HYS: Hoehn-Yahr Stage; MDS-UPDRS = Movement Disorders Society Sponsored version of Uniﬁed Parkinson's Disease Rating Scale;
UDysRS=Uniﬁed Dyskinesia Rating Scale.
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